50% Off Your Order*
Easter Savings!!
Availability: In stock
Unit Size | 10 mg/ vial |
Unit Quantity | 1 vial |
Purity (Mass Spectrometry and UV) | 99.0% |
Appearance | Lyophilized White Powder |
Source | Chemical Synthesis |
Storage |
Lyophilized Blend CJC 1295 NO DAC with GHRP-6 is Stable at roomTemperature for 90 days, however it is best to store in a freezer below - 8c for any extended period of time. After reconstitution Blend CJC 1295 NO DAC with GHRP-6 should be refrigerated at temperatures not to exceed 35 F. |
Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
CJC 1295 NO/DAC with GHRP-6 is a synthetic analog of the growth hormone-releasing hormone (GHRH). This specific formulation also contains growth hormone-releasing peptide-6 (GHRP-6). This peptide is derived from GHRH 1-29, another synthetic peptide also known as sermorelin. CJC-1295 contains 30 amino acids and has a molecular weight of 3647.16 g/mol. CJC-1295 can be formulated with or without the drug affinity complex (DAC), which was designed originally to improve the half-life of the peptide. This allows it to bioconjugate with albumin in the bloodstream, preventing its degradation and increasing its therapeutic window.1 Endogenous GHRH has a half-life of around 7 minutes.2 However, this formulation does not have the DAC attached to CJC-1295. One study using a mouse model with GHRH knocked out found that CJC-1295 treatment causes normal growth hormone release without interfering with downstream pathways, such as insulin-like growth factor-1 (IGF-1) release.3 This allows researchers to utilize the peptide in a biologically relevant setting. GHRP-6 is a synthetic analog of ghrelin, which functions endogenously to release growth hormone and stimulate appetite. It binds to the growth hormone secretagogue receptor (GHS-R). Since CJC-1295 and GHRP-6 have similar functions, many studies have found that these peptides can work synergistically to increase growth hormone levels. Since CJC-1295 does not interfere with the pulsatile release of growth hormone, it can be combined with GHRP-6 to enhance baseline levels.4,5 Studies show that together, these peptides play a role in promoting muscle and bone strength, along with enhanced wound healing and recovery from stroke.4,6,7 While studies have used CJC-1295 and GHRP-6, this formulation is not approved for these purposes. CJC-1295 NO/DAC with GHRP-6 is for laboratory research use only. It is available at a concentration of 5mg X 2 = 10mg per vial for use in vitro studies.
References: 1. Jette L, Leger R, Thibaudeau K, et al. Human Growth Hormone-Releasing Factor (hGRH) 1-29 - Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005 Jul;146(7):3052-3058. 2. Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. 3.Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. 4. Mayola MF, Betancourt L, Molina-Kautzman A, et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. Int Wound J. 2018 Aug;15(4):538-546. 5. Huang H, Chen X, Han Q, et al. The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice. Neuropharmacology. 2019 Sep;155:31-43. 6. Mari YM, Mayola MF, Barreto AA, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plast Surg Int. 2016;2016:4361702. 7. Subiros N, Perez-Saad HM, Berlanga JA, et al. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016 Mar;38(3):187-95.